This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL) and Fennec Pharmaceuticals (FENC)

Tipranks - Tipranks - Thu Apr 23, 10:02AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbCellera Biologics (ABCL) and Fennec Pharmaceuticals (FENC) with bullish sentiments.

Claim 30% Off TipRanks

AbCellera Biologics (ABCL)

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on AbCellera Biologics, with a price target of $11.00. The company’s shares closed last Wednesday at $4.12.

According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of 48.0% and a 69.4% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and Sionna Therapeutics, Inc. ;'>

Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $8.33, which is a 105.7% upside from current levels. In a report issued on April 15, Truist Financial also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Fennec Pharmaceuticals (FENC)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Fennec Pharmaceuticals today. The company’s shares closed last Wednesday at $6.59.

According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of 35.3% and a 59.0% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Xtant Medical Holdings, and Diamedica Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fennec Pharmaceuticals with a $15.00 average price target, a 127.3% upside from current levels. In a report issued on April 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).